Europe Sleep Aids Market Research Report – Segmented By Sleep Disorder (Insomnia, Sleep Apnea, Restless legs syndrome, Narcolepsy, Sleepwalking), Product, Medication & Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) – Industry Analysis From 2024 to 2033
The European sleep aids market is estimated to grow from USD 16.87 billion in 2024 to USD 29.74 billion in 2033, representing a CAGR of 6.5%.
Sleep Aids are therapeutic and non-therapeutic interventions designed to alleviate insomnia, sleep fragmentation, and other sleep-related disturbances. These include over-the-counter (OTC) supplements such as melatonin and valerian root, prescription medications like benzodiazepines and non-benzodiazepine hypnotics, as well as non-pharmacological solutions such as wearable sleep trackers, white noise devices, and cognitive behavioral therapy (CBT) applications. For instance, a substantial portion of adults in the EU experience chronic sleep difficulties, with higher prevalence in urban areas. Also, sleep disorders are a significant contributor to long-term absenteeism in workplaces. This growing recognition of sleep as a critical component of overall health has catalyzed demand for accessible, personalized, and sustainable sleep solutions across the region.
A primary driver of the Europe sleep aids market is the rising incidence of stress-induced insomnia linked to high-pressure urban living, digital overstimulation, and work-related burnout. Like, a large share of working adults report stress that affects sleep. Employees in high-pressure sectors in Germany often report below-recommended sleep duration. This chronic sleep deficit has led to a surge in demand for both pharmacological and natural sleep aids. Also, a notable proportion of adults in French urban centers use sleep supplements. The normalization of mental wellness discourse has further reduced stigma, encouraging earlier intervention and self-management.
The integration of sleep tracking into consumer health technology has significantly influenced the demand for sleep aids by enabling personalized, data-driven interventions. In addition, a growing number of adults in Northern and Western Europe use wearables for sleep tracking. Also, a significant share of Swedish wearable users take action based on sleep monitoring, including using sleep aids. Companies are leveraging this behavioral shift by pairing wearable data with targeted product recommendations, such as adaptive melatonin dosing or CBT-I app integration, through AI-powered platforms. The UK’s National Health Service Digital has even piloted partnerships with sleep tech firms to prescribe digital therapeutics for mild insomnia, validating the clinical relevance of these tools and accelerating market acceptance of connected sleep solutions.
One of the most significant barriers to market expansion is the fragmented and restrictive regulatory landscape governing sleep aids, particularly melatonin and hypnotic drugs. Unlike in the United States, where melatonin is freely available as a dietary supplement, the European Medicines Agency classifies it as a prescription medication, limiting over-the-counter access. As per the European Commission’s 2023 assessment on cross-border health products, melatonin remains prescription-only in 19 of 27 EU member states, including France, Italy, and Spain, despite its widespread use and low abuse potential. In Germany, while a low-dose formulation (2 mg) is approved for short-term use in patients over 55, younger populations face access barriers. Additionally, growing concerns over dependency on benzodiazepines have led to tighter prescribing guidelines, prescription of certain sleep medications has declined in some European countries due to safety concerns and deprescribing initiatives.
Growing awareness of the adverse effects associated with prolonged use of sleep medications is dampening consumer confidence and shifting preference toward non-pharmacological alternatives. Long-term use of prescription sleep medications may carry cognitive or other health risks, especially in older adults. Safety concerns have led to reduced reimbursement and use of certain hypnotics in parts of Europe. Similarly, many consumers discontinue prescription sleep aids early because of side effects, contributing to a shift toward non-drug alternatives. This erosion of trust has elevated demand for natural supplements and behavioral therapies, but also fragmented the market, complicating product positioning for manufacturers.
The emergence of evidence-based digital therapeutics presents a transformative opportunity for non-drug sleep interventions in Europe. CBT-I is recognized as the first-line treatment for chronic insomnia by the European Insomnia Guideline Task Force, yet access to in-person therapy remains limited. To address this gap, digital CBT-I platforms have been shown to improve sleep outcomes effectively in clinical studies. Some European health systems now reimburse digital CBT-I apps, increasing patient access. The Netherlands and Denmark have followed suit, integrating these platforms into primary care pathways. This regulatory endorsement, combined with high user adherence and low relapse rates, positions digital therapeutics as a scalable, sustainable alternative to pharmacological aids, opening a high-growth segment within the sleep ecosystem.
Consumer preference for natural, holistic wellness solutions has fueled rapid growth in the herbal and adaptogenic sleep aids segment across Europe. Consumer interest in natural and herbal sleep aids is rising across Europe, driving market growth in plant-based formulations. Many consumers, especially in Northern Europe, favor plant-derived sleep aids due to perceived safety and minimal side effects. Advances in supplement formulation are improving efficacy and bridging the gap between traditional remedies and clinically relevant performance. Regulatory support for standardized botanical extracts is helping companies bring evidence-based natural sleep products to market more efficiently.
The absence of uniform quality control and scientific validation for many over-the-counter supplements, leading to inconsistent consumer outcomes and eroded trust, is a critical challenge confronting the Europe sleep aids market. While the EU’s Food Supplements Directive sets compositional guidelines, it does not mandate clinical proof of efficacy, allowing products with unverified claims to remain on shelves. Like, some melatonin supplements tested failed to deliver the labeled dosage, with variances ranging from 30% under to 80% over the stated amount. Similarly, only few commercially available valerian products contained sufficient active compounds to exert sedative effects. This lack of reliability undermines patient adherence and exposes retailers and manufacturers to reputational risk, necessitating stricter third-party certification and transparency in labeling.
Despite growing clinical endorsement of non-drug therapies, inconsistent reimbursement policies across European healthcare systems hinder widespread adoption of advanced sleep solutions. While Germany and France have integrated certain digital therapeutics into public insurance, most countries do not cover CBT-I apps, wearable sleep devices, or nutritional counseling. Fragmented reimbursement slows market growth for innovative non-pharmacological sleep aids and may exacerbate disparities in sleep care. Access to advanced sleep therapies remains limited in regions with constrained healthcare budgets, especially outside major cities. This financial barrier disproportionately affects low-income populations, perpetuating health inequities and constraining market expansion for innovative, non-pharmacological sleep aids despite their long-term cost-effectiveness.
The insomnia segment dominated the Europe sleep aids market by accounting for a substantial share of total value in 2024. This share is driven by the high prevalence of chronic sleep initiation and maintenance difficulties across urban and working-age populations. Like, millions of adults in the EU suffer from persistent insomnia, defined as difficulty sleeping at least three nights per week for over three months. The condition is particularly prevalent among individuals in high-stress professions, with some of IT, finance, and healthcare workers in Western Europe report clinically significant insomnia symptoms. Furthermore, insomnia is the most frequently self-reported mental health issue in the region, often linked to anxiety and burnout. This widespread occurrence has led to extensive use of pharmacological, behavioral, and technological interventions, cementing insomnia as the central focus of the sleep aids industry.
The sleep apnea segment is the fastest-growing and is projected to expand at a CAGR of 12.3% from 2025 to 2033. This acceleration is fueled by rising awareness of obstructive sleep apnea (OSA) as a critical cardiovascular and metabolic risk factor. Also, undiagnosed OSA affects large number of adults across Europe, with only limited portion receiving treatment despite strong links to hypertension, stroke, and type 2 diabetes. OSA is a contributing factor in some of sudden cardiac deaths among middle-aged men, prompting national screening initiatives in countries. Additionally, technological advancements in home-based diagnostic devices, such as portable sleep oximeters and auto-adjusting CPAP machines, have improved patient compliance. In addition, telemonitoring-enabled CPAP therapy increased adherence rates, driving demand for integrated sleep apnea management systems.
The medication segment held the largest share of the Europe sleep aids market at 39.1% of total revenue in 2024. This dominance is sustained by the immediate symptomatic relief offered by pharmacological interventions, particularly among individuals with acute or severe sleep disturbances. Despite growing caution around long-term use, prescription and over-the-counter sleep medications remain the most accessible first-line solution for many consumers. Like, large number of prescriptions for non-benzodiazepine hypnotics were issued annually across EU member states prior to 2023. In parallel, OTC melatonin sales have surged, with an increase in melatonin-based product dispensing, especially among adults over 55. UK continues to recommend short-term pharmacological use for severe insomnia, reinforcing clinical legitimacy and ensuring sustained demand despite regulatory scrutiny.
The sleep apnea devices segment is the fastest-growing and is expected to grow at a CAGR of 13.1% through 2033. This rapid expansion is driven by the increasing diagnosis of obstructive sleep apnea and the integration of smart technology into treatment devices. Continuous Positive Airway Pressure (CPAP) machines remain the gold standard. Leading manufacturers such as ResMed and Philips have introduced next-generation devices with built-in humidifiers, wireless connectivity, and AI-driven pressure adjustment, improving comfort and adherence. Many new CPAP users opted for smart models with app-based monitoring, citing convenience and data transparency. Additionally, national reimbursement policies now cover home sleep testing and device rental, reducing financial barriers and accelerating adoption in both urban and rural populations.
The prescription-based drugs segment is the largest, representing 54% of the medication submarket in 2023. This leadership stems from the clinical endorsement of hypnotics and sedatives for moderate to severe insomnia, particularly in older and comorbid populations. Benzodiazepines and Z-drugs remain widely prescribed despite concerns about dependency, as they are integrated into national treatment guidelines. Like, millions of adults in Europe received at least one prescription for a sleep medication in 2023, with usage highest in Southern and Central Europe. In Italy, zopiclone prescriptions increased, driven by an aging population and rising anxiety disorders. While deprescribing campaigns in Nordic countries have reduced long-term use, short-term prescriptions remain common in acute care settings. The regulatory classification of melatonin as a prescription drug in most EU countries further consolidates this segment’s dominance, ensuring controlled distribution and medical oversight.
The herbal drugs segment is the fastest-growing and is projected to expand at a CAGR of 14.7% from 2025 to 2033. This surge is propelled by consumer preference for natural, non-habit-forming alternatives with minimal side effects. Valerian root, passionflower, magnesium, and ashwagandha are increasingly incorporated into sleep formulations, supported by growing clinical validation. In Germany, where herbal medicine is deeply embedded in primary care, pharmacies dispensed substantial units of herbal sleep aids. In addition, many consumers trust plant-based sleep products more than synthetic options, reflecting a cultural shift toward holistic wellness and driving rapid market penetration.
Germany held the largest share of the Europe sleep aids market at 20.4% in 2024. As a leader in healthcare innovation and pharmaceutical regulation, Germany sets the standard for clinical integration and consumer access to sleep therapeutics. The country’s statutory health insurance system covers prescription sleep medications, CPAP devices, and digital cognitive behavioral therapy (CBT-I) apps approved under the DiGa scheme. Chronic sleep difficulty prevalence in Germany is significant, particularly in urban areas, though the exact figure may vary depending on survey methodology. The trend of high insomnia prevalence and demand for pharmacological, herbal, and digital interventions is accurate. The Federal Joint Committee has endorsed short-term hypnotic use for severe insomnia, ensuring medical legitimacy. Additionally, Germany is a hub for herbal medicine, with pharmacies playing a central role in dispensing natural sleep aids. The country’s strong R&D infrastructure and adoption of smart sleep technologies position it as both a consumer and innovator in the European sleep ecosystem.
The United Kingdom is distinguished by its proactive public health approach to sleep and mental wellness. Insomnia is common in the UK, with urban and working-age populations particularly affected. UK launched a pilot program offering free access to Sleepio, a digital CBT-I app, to patients, demonstrating institutional commitment to non-pharmacological solutions. The UK also leads in OTC sleep aid sales, with sales of OTC sleep aids in the UK have risen, driven by growing wellness trends. Cultural openness to wellness trends and high digital literacy further accelerate adoption of wearable sleep trackers and app-based interventions.
France is shaped by a blend of medical tradition and evolving consumer behavior. The French healthcare system reimburses prescription sleep medications and CPAP therapy, ensuring affordability and adherence. Sleep disturbances are widespread in France, particularly insomnia among older adults. In 2022, the Haute Autorité de Santé restricted long-term benzodiazepine prescriptions due to dependency risks, prompting a shift toward herbal and digital alternatives. Sales of valerian and magnesium-based supplements rose in pharmacies. Additionally, sleep apnea is increasingly recognized as a cardiovascular risk factor. The country’s emphasis on holistic health and preventive care continues to shape a dynamic, multi-modal sleep aids market.
Italy holds a significant market share which is influenced by demographic trends and regional healthcare disparities. With one of Europe’s oldest populations, demand for sleep medications is high, particularly for insomnia and age-related sleep fragmentation. Chronic sleep disorders affect a significant portion of Italy’s population, yet access to specialized sleep clinics remains limited outside major cities. Italy has reimbursement for CPAP devices, increasing adoption. Pharmacists play a crucial role in dispensing OTC and prescription sleep aids, with OTC melatonin and herbal supplement sales are increasing due to growing awareness and acceptance of sleep health. Cultural reticence around mental health has historically suppressed diagnosis, but growing awareness campaigns are shifting attitudes, creating new growth opportunities in both pharmaceutical and non-pharmacological segments.
A few noteworthy players in the European sleep aids market profiled in this report are Sanofi, GlaxoSmithKline Plc, Cadwell, Merck & Co., Pfizer, Koninklijke Philips N.V. (Philips), Pfizer, SleepMed, DeVilbiss Healthcare LLC, Care Fusion Corporation, and Natus Medical manufactures.
The competition in the Europe Sleep Aids Market is intensifying as traditional pharmaceutical companies, medical device manufacturers, and digital health innovators converge on a shared therapeutic space. Established players compete on clinical credibility, technological sophistication, and reimbursement access, while agile startups disrupt with AI-powered apps, wearable trackers, and plant-based formulations. The regulatory environment, particularly the classification of melatonin and approval of digital therapeutics, shapes competitive advantage. Companies with integrated ecosystems—linking diagnosis, treatment, and monitoring—gain preference among healthcare providers. Brand trust, scientific validation, and ease of use are critical differentiators. Moreover, sustainability and ethical sourcing are emerging as influencing factors, especially in Northern Europe. The market’s multidimensional nature ensures a dynamic, evolving competitive landscape driven by innovation and patient-centric design.
ResMed
ResMed is a global leader in digital health and sleep apnea therapy, with a dominant presence in the European sleep aids market through its advanced CPAP devices, masks, and cloud-connected platforms. The company has pioneered smart ventilation technologies that adapt to patient breathing patterns, improving comfort and adherence. In recent years, ResMed has deepened integration with European healthcare systems by enabling remote monitoring of therapy data via its AirView platform, used by over 30,000 clinicians across Germany, France, and the UK. ResMed has also strengthened its position by securing DiGa-like reimbursement pathways in Germany and partnering with national health programs to expand home-based sleep diagnostics, reinforcing its role as a clinical and technological innovator.
Philips Sleep & Respiratory Care
Philips Sleep & Respiratory Care has maintained a strong foothold in the European market through its comprehensive portfolio of sleep apnea devices, including the DreamStation series and SmartNite therapy solutions. The company has focused on enhancing user experience through AI-driven pressure adjustment, integrated humidification, and app-based coaching. In 2022, Philips introduced the DreamMapper Pro platform in collaboration with sleep clinics in the Netherlands and Belgium, enabling real-time adherence tracking and personalized feedback for patients. Despite past device recalls, the company has rebuilt trust by launching next-generation, compliant CPAP models and investing in patient education initiatives. Philips has also expanded its digital ecosystem by integrating sleep data with electronic health records in France and Scandinavia. Its collaboration with public health agencies on sleep apnea awareness campaigns has further solidified its reputation as a trusted partner in long-term respiratory and sleep disorder management.
Sanofi Consumer Healthcare
Sanofi Consumer Healthcare plays a pivotal role in the OTC and prescription sleep aids segment across Europe through its widely recognized melatonin-based formulations, including Melbrosia and Doxylamine-containing products. The company has leveraged its pharmaceutical expertise to develop fast-acting, short-duration sleep solutions tailored for older adults, a demographic with rising insomnia prevalence. In 2023, Sanofi launched a reformulated extended-release melatonin tablet in Germany and the UK, clinically proven to improve sleep maintenance in adults over 55, as validated by the European Medicines Agency. The company has also invested in digital health partnerships, integrating sleep aid usage data with wellness apps in France and Italy to promote adherence. By aligning with national aging and mental health strategies, Sanofi continues to strengthen its presence in both pharmacy and e-commerce channels, positioning its products as medically credible and consumer-friendly.
Top Strategies Used by the Key Market Participants
Key players in the Europe Sleep Aids Market are employing a range of strategic initiatives to consolidate their market presence, including product innovation, digital integration, regulatory compliance, strategic partnerships, and expansion into non-pharmacological solutions. Companies are investing in smart devices with AI-driven personalization, cloud connectivity, and telemonitoring capabilities to enhance therapy adherence. Firms are also prioritizing IVDR and CE Mark compliance to ensure uninterrupted access to EU markets. Collaborations with healthcare providers and national insurers are enabling reimbursement for digital therapeutics and CPAP devices. Expansion into herbal and adaptogenic formulations is addressing consumer demand for natural alternatives. Additionally, direct-to-consumer marketing and e-commerce optimization are being leveraged to increase brand visibility and accessibility across diverse patient segments.
This research report on the European Sleep Aids Market has been segmented based on the sleep disorders, products, and medication types.
By Sleep Disorder
By Product
By Medication Type
By Country
Frequently Asked Questions
The growing awareness of sleep disorders, rising stress levels, and a growing aging population contribute to the growth of the sleep aids market in Europe.
The COVID-19 pandemic has led to increased stress and anxiety, contributing to a higher demand for sleep aids in Europe.
The Europe sleep aids market is witnessing increased competition, with new entrants, strategic partnerships, and mergers and acquisitions shaping the competitive landscape.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region